Aripiprazole data summary: efficacy and safety results
Underutilization of LAIs
Commentary by Dr. Ofer Agid, Centre for Addiction and Mental Health, Associate Professor of Psychiatry, University of Toronto, Toronto, Canada.

A once-monthly long-acting injectable (LAI) formulation of aripiprazole (Abilify Maintena; Otsuka Pharmaceuticals Canada Inc.) has now been approved by Health Canada for maintenance treatment of adult patients with schizophrenia.